+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

RedHill Biopharma Ltd (RDHL) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 58 Pages
  • June 2023
  • GlobalData
  • ID: 4278717
RedHill Biopharma Ltd (RDHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

RedHill Biopharma Ltd (RedHill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer. The company's commercial product portfolio consists of branded prescription drugs including a combination of omeprazole, amoxicillin and rifabutin omeprazole; naloxegol; and rifamycin. RedHill is investigating its pipeline candidates for the treatment of Crohn's disease, non-tuberculous mycobacterial infection (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleanser, cancer and novel coronavirus disease (COVID-19). The company has a subsidiary in the US. RedHill is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd Key Recent Developments

  • May 22, 2023: RedHill provides R&D update
  • Apr 28, 2023: RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
  • Nov 14, 2022: RedHill Biopharma reaches agreement in principle with HCR to extinguish all debt obligations in exchange for Movantik
  • Oct 03, 2022: RedHill's oral broad-acting antivirals, opaganib and RHB-107, inhibit dominant omicron sub-variant BA.5

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • RedHill Biopharma Ltd - Key Facts
  • RedHill Biopharma Ltd - Key Employees
  • RedHill Biopharma Ltd - Key Employee Biographies
  • RedHill Biopharma Ltd - Major Products and Services
  • RedHill Biopharma Ltd - History
  • RedHill Biopharma Ltd - Company Statement
  • RedHill Biopharma Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate
Section 2 - Company Analysis
  • Company Overview
  • RedHill Biopharma Ltd - Business Description
  • Product Category: Licensing Revenue
  • Performance
  • Product Category: Movantik
  • Performance
  • Product Category: Other revenues
  • Performance
  • R&D Overview
  • RedHill Biopharma Ltd - Corporate Strategy
  • RedHill Biopharma Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • RedHill Biopharma Ltd - Strengths
  • RedHill Biopharma Ltd - Weaknesses
  • RedHill Biopharma Ltd - Opportunities
  • RedHill Biopharma Ltd - Threats
  • RedHill Biopharma Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • RedHill Biopharma Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 22, 2023: RedHill provides R&D update
  • Apr 28, 2023: RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
  • Nov 14, 2022: RedHill Biopharma reaches agreement in principle with HCR to extinguish all debt obligations in exchange for Movantik
  • Oct 03, 2022: RedHill's oral broad-acting antivirals, opaganib and RHB-107, inhibit dominant omicron sub-variant BA.5
  • Jul 12, 2022: RedHill announces new H. pylori and COVID-19 data publication and presentations at leading upcoming scientific conferences
  • Jun 23, 2022: RedHill Biopharma announces Q1/22 highlights: On track for positive cash from operations in H2/22
  • Jun 17, 2022: RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23 2022
  • Mar 17, 2022: RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
  • Mar 16, 2022: RedHill, Kukbo sign licence deal for oral Covid-19 therapy in South Korea
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • RedHill Biopharma Ltd, Key Facts
  • RedHill Biopharma Ltd, Key Employees
  • RedHill Biopharma Ltd, Key Employee Biographies
  • RedHill Biopharma Ltd, Major Products and Services
  • RedHill Biopharma Ltd, History
  • RedHill Biopharma Ltd, Other Locations
  • RedHill Biopharma Ltd, Subsidiaries
  • RedHill Biopharma Ltd, Affiliate
  • RedHill Biopharma Ltd, Key Competitors
  • RedHill Biopharma Ltd, Ratios based on current share price
  • RedHill Biopharma Ltd, Annual Ratios
  • RedHill Biopharma Ltd, Interim Ratios
  • RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • RedHill Biopharma Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • RedHill Biopharma Ltd, Performance Chart (2018 - 2022)
  • RedHill Biopharma Ltd, Ratio Charts
  • RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Vascular Biogenics Ltd
  • Unipharm Ltd
  • Hayat Pharmaceutical Industries
  • Dexcel PT Israel Ltd
  • BioLineRx Ltd
  • SciSparc Ltd